ClinicalTrials.gg
CompletedNCT00101842Updated Aug 29, 2006

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

A Phase 1/2 interventional study of Pemetrexed and Gemcitabine in Carcinoma, Transitional Cell, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-08-29.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing gemcitabine in Carcinoma, Transitional Cell — 3 open to participants now, 8 under way, 1 of them phase 3. Gemcitabine · Carcinoma, Transitional Cell.

Enrollment
11th of 27
61 · median 54
Started
2004
with 1 other
Phase 1/2
4 of 27
none open now
Registered
1st of 27
by date
Lead sponsor
2 of 27
Eli Lilly and Company

Among the 27 studies testing gemcitabine in Carcinoma, Transitional Cell, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 4 in phase 1/2, and was the 1st registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 179 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

3 of the 27 studies testing gemcitabine in Carcinoma, Transitional Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing gemcitabine in Carcinoma, Transitional Cell, or all of them as a file.
02

Study summary

The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patients with advanced bladder cancer live longer; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can make your tumor smaller or disappear, and for how long.

03

Conditions studied

  • Carcinoma, Transitional Cell
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven bladder cancer
  • No prior chemotherapy for metastatic disease except before or after surgery, which was completed 6 months before enrollment
  • Prior radiation allowed, if it is not the only site of and if completed 3 weeks before enrollment
  • 18 years of age and older

Exclusion criteria

Exclusion Criteria:

  • Pure adeno- or squamous urothelial cancer
  • that causes symptoms
  • Have not received treatment within the last 30 days with a drug that has not received regulatory approval for any indication
  • Inability to take dexamethasone, folic acid or vitamin B12, according to the protocol
  • fluid collection in the lungs or abdomen that cannot be controlled
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Toxicity will be measured by standard grading methods.

Secondary outcomes

  1. Response will be measured by Response Evaluation Criteria in Solid Tumors (RECIST).

  2. Duration of response is defined as time from first objective assessment of CR or PR to first time of progression or death from any cause.

  3. Time to progressive disease is defined as time from enrollment to first date of disease progression.

  4. Time to treatment failure is defined as time from enrollment to first observation of disease progression, death of any cause or early discontinuation of treatment.

  5. Survival time is defined as time from enrollment to death from any cause.

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician.
    Dallas, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2005
First posted
Jan 17, 2005
Start
Dec 2004
Completion
Jul 2006
Last update
Aug 29, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Aug 29, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00101842
First posted
Jan 17, 2005
Start date
Dec 2004
Completion
Jul 2006
Last update
Aug 29, 2006

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pemetrexed · Gemcitabine · Cisplatin

Start the discussion